Pharmaceuticals Invest To Speed Drug Trials - InformationWeek

InformationWeek is part of the Informa Tech Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them.Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Pharmaceuticals Invest To Speed Drug Trials

Venture capital money might be hard to come by for young tech companies these days, but some recent investments show a new trend of pharmaceutical giants financing IT start-ups to develop ways to speed clinical drug trials.

Clinical trials are a "major bottleneck" in the development of new drugs, says Michael Carusi, general partner at venture capital firm Advanced Technology Ventures. Every day lost in slow trials costs drug companies millions of dollars, he says, because the short patent life of the drug is running out, and because other companies are coming to market quicker with copycat products.

On April 18, pharmaceutical giant Eli Lilly announced it would invest an undisclosed amount in start-up 1747 Inc., developers of a system that automates the clinical trial process and uses the Internet to speed interaction with test subjects. The investment was made through the e.Lilly venture fund, founded in January with a $50 million annual budget. According to the company, the fund is designed to support early-stage development companies working on E-business products to benefit the development of pharmaceuticals.

Late last year, the nation's second-largest drug maker, Merck & Co., formed a new subsidiary, Merck Capital Ventures LLC, which plans to invest $100 million over the next two years into private businesses focused on pharmaceutical development using the Internet and other information technologies. In March, the fund made its first investment, contributing to a $27 million financing round for Acurian Inc., another manufacturer of Web-based trial systems.

Carusi says pharmaceutical companies see these investments as external R&D, allowing them to build tools that they wouldn't be able to develop on their own. "Particularly in the IT area, it's just not an area of competence for them," he says. "There's a level of scale required larger than what Eli or Merck could bring."

We welcome your comments on this topic on our social media channels, or [contact us directly] with questions about the site.
Comment  | 
Print  | 
More Insights
2021 State of ITOps and SecOps Report
2021 State of ITOps and SecOps Report
This new report from InformationWeek explores what we've learned over the past year, critical trends around ITOps and SecOps, and where leaders are focusing their time and efforts to support a growing digital economy. Download it today!
InformationWeek Is Getting an Upgrade!

Find out more about our plans to improve the look, functionality, and performance of the InformationWeek site in the coming months.

Remote Work Tops SF, NYC for Most High-Paying Job Openings
Jessica Davis, Senior Editor, Enterprise Apps,  7/20/2021
Blockchain Gets Real Across Industries
Lisa Morgan, Freelance Writer,  7/22/2021
Seeking a Competitive Edge vs. Chasing Savings in the Cloud
Joao-Pierre S. Ruth, Senior Writer,  7/19/2021
Register for InformationWeek Newsletters
Current Issue
Monitoring Critical Cloud Workloads Report
In this report, our experts will discuss how to advance your ability to monitor critical workloads as they move about the various cloud platforms in your company.
White Papers
Twitter Feed
Sponsored Live Streaming Video
Everything You've Been Told About Mobility Is Wrong
Attend this video symposium with Sean Wisdom, Global Director of Mobility Solutions, and learn about how you can harness powerful new products to mobilize your business potential.
Sponsored Video
Flash Poll